There are no previous reports about the molecular defects of alpha and beta thalassemia in Yemeni sickle cell disease (SCD) patients, except one report about alpha thalassemia in Yemeni SCD children living in Riyadh Saudi Arabia. The aim of this clinical cross-sectional study was directed to determine the genetic defects of α and β-thalassemia in Yemeni sickle cell disease children and to determine their prevalence in Taiz governorate Yemen where the prevalence of sickle-cell trait HbAS is about 8.2%. Blood samples were collected from 145 SCD children to determine the complete blood count, sickling tests and hemoglobin fraction analysis by high pressure liquid chromatography (HPLC) method .Serum ferritin was determined in serum of those patients who had low mean cell volume (MCV) and low mean cell hemoglobin (MCH) to exclude presence of iron deficiency anemia. The DNA was analyzed in 30 patients with thalassemia indices after exclusion of iron deficiency anemia using polymerase chain reaction (PCR) based techniques namely (The β-Globin and α-globin test Strips assay and Gap PCR). This study showed that in Taiz governorate the overall prevalence of SCD with thalassemia was (27.5%) and according to DNA analysis the prevalence of (HbSS+α-thalassemia) and (HbS/β 0 -thalassemia) were 18.5% and 5.9%, respectively. For first time in Taiz and Yemen the present study confirms presence of different combination between sickle cell gene, β 0 -Thalassemia and α-Thalassemia genes which means presence of these genetic diseases in Yemeni population. There were 8 patients (26.6%) with (β S / β 0 ) -thalassemia and 22 (73.3%) with (HbSS/ α-thalassemia). There were three β thalassemia mutations detected the most common mutation was the ( IVS II-1 A>T ) type with frequency of (75%), and the α-thalassemia deletion found in Yemeni SCD children was of right ward deletion (-3.7 kb), and 17 patients (68%) had one gene deletion and 8 patients (32%) two gene deletions.
INTRODUCTION
The term Sickle Cell Disease (SCD) includes all clinical forms characterized by the presence of hemoglobin S (HbS) which leads to the sickling phenomenon and formation of sickle red blood cells in the peripheral blood, leading to varying degree of hemolysis and intermittent episodes of vascular occlusion. The interaction of SCD with thalassemia and certain variant hemoglobins also leads to sickling, and may affect its clinical picture. This property of HbS is the result of a point mutation in which a single nucleotide in the 6 th position of the β globin gene is replaced with another nucleotide that led to replacement of glutamic acid in the 6 th position of the β globin chain by a molecule of valine ( β S 6 AT ) [1] .
The thalassemia syndrome has two major forms known as α and β-thalassemia, and are characterized by quantitative deficiency of either α-globin or β-globin chains respectively. Over 200 different mutations leading to β-thalassemia have been characterized world wide [1] . α-Thalassemia expression depends on the number of α-globin genes present in the genome. Thus normal subjects carry four α-globin genes (αα/αα) and a loss of one or two genes (-α/αα), (--/αα) leads to minor forms of α-thalassemia which present a variety of expression and is associated with microcytic and hypochromic anemia. In addition non-deletion variant of α-thalassemia was also reported in several populations. The most common α-thalassemia deletions in Africa, Middle East, and Arabian Peninsula are (-3.7 kb) and (-4.2 kb) [2] .
Homozygous sickle cell disease (HbSS) is the most common form of sickle cell disease and is responsible for (60-70%) of cases of sickle cell disease in the world [2] . Interaction of HbS with thalassemia has been reported in many studies [2, 3] . The high prevalence of these genetic defects in certain human populations may be due to increasing consanguinity and tribal intermarriage [3] . Yemen is located in the south west corner of Arabian Peninsula, and has a population of approximately 22.5 million inhabitants [4] . The overall prevalence of sickle-cell trait HbAS in Yemen is (2.2%), with a higher frequency in the mid-western region where Taiz city is located than in the central and eastern areas, and the prevalence of HbAS in Taiz is about (8.2 %) [5] .
There are no previous reports on the prevalence and molecular defects of (α) or (β) thalassemia in Yemeni SCD patients, except one showing that the coexistence of (α-thalassemia) in 26 Yemeni children with SCD living in Riyadh was (57.7%), and the gene deletion was of (-3.7 kb ) type [3] . The major goal of this study is to determine the molecular bases of α and β -thalassemia among Yemeni SCD children, and their prevalence for first time in Taiz and Yemen. This study is important for health authorities; if national programs of screening health education and genetic counseling are to be considered in the future. Also such data are relevant for Yemeni expatriates who are to receive medical attention abroad and of anthropological interest.
MATERIAL AND METHODS

Patients
Over a period of one year (May 2007-May 2008), we studied 145 patients; 80 males (55.2%) and 65 females (44.8%), aged between (6 months to 15 years) who came from different districts of Taiz governorate. 24 patients (16.5%) came from urban area (Taiz City), and 121 patients (83.5%) came from rural areas. Distribution according to the geographical origin shows that most patients came from Mawia, Taiz City, Khadeer and Almisrakh (Table1). 
Hematology and biochemical analysis
After informed consent was taken, two venous blood samples (1 into EDTA tube and 1 clotted) were collected from each patient. Whole blood was used to determine the complete blood counts using an automated coulter counter type Sysmex 101-N (Sysmex-Toa Medical Electronics Co. Kobe, Japan), erythrocyte sedimentation rate (ESR), sickling test (using the sodium metabisulfate method) were measured. Peripheral smears which were prepared and air-dried and blood cells morphology was studied after staining of the smears with Giemsa stain. Reticulocyte count was determined by reading their percentage in prepared smears after staining of blood with new methylene blue. The hemoglobin electrophoresis was done for all sickle cell positive samples, and was carried out using Helena TITAN III instruments on cellulose acetate plate in alkaline buffer. Confirmation of presence of hemoglobin S and quantification of Hemoglobin S, A2, and F were done by BIO-RAD D10 instruments (Hercules, company, CA, USA) using the method of high pressure liquid chromatography (HPLC) (Fig. 1) . Serum was separated by centrifugation of the blood and was used for the serum ferritin level determination only in serum of those patients with low MCV and MCH to exclude coexistence of iron deficiency. The serum ferritin was determined by using the AxSym fluorescence microparticle enzyme immunoassay method (Abbott).
All data were collected and registered in clinical sheets, and all information was worked out in personal computer and the statistical data was performed using Epi-Data 3.2 version program and Excel-XP.
DNA analysis in Yemeni SCD children from Taiz
In June 2008 another 10 mL venous blood samples were collected into EDTA tubes from 30 patients out of 40 patients classified as SCD/thalassemia 10 patients were absent in the date of blood collection. Blood samples were sent to Jordan for DNA analysis which was provided by department of hematology at Princess Iman for Research and Laboratory Sciences Centre at King Hussein Medical City in Jordan Amman.
The DNA was analyzed using polymerase chain reaction (PCR) based technique namely; The reverse hybridization dot blotting method using commercial β-Globin and α-globin test strips assay. In this method, PCR amplification was carried out using biotinlyated primers followed by hybridization of the amplified PCR product to 1 β-Globin test Strip and to 2 α-globin test Strips (test strips A & B). These test strips containing allele-specific oligonucleotide probes to wild type and mutant alleles, immobilized as an array of parallel lines. After hybridization, bound biotinylated sequences were detected using streptavidin phosphatase and color substrate. The β-globin and α-globin test Strips are commercial products imported from Vienna Lab Diagnostics GmbH Vienna Austria. The results of α-globin Strip Assay were confirmed using Gap-PCR method [9] .
RESULTS
1-Hematological and biochemical results
The mean values of hematological parameters of all patients are shown in table 2. The sickling tests were positive in all the samples, and the hemoglobin analysis by HPLC method showed no hemoglobin A (HbA) was detected in any of them.
Serum ferritin was determined in those patients with low MCV/MCH to exclude co-existence of iron deficiency, and the results were as the follow: All 40 samples showed normal or increased ferritin level . ]( β S 6 AT ) with coexistence of α -thalassemia deletion type (-3.7 kb) in one of the 4 genes in 14 samples (63.6 % ) (αα / α -) ( α -3.7 α / α α ) and 2 gene deletions of the 4 alfa-genes (α-/-α) (α -3.7 α / α -3.7 α ) in 8 samples (36.4%) ( Table 4 ).
The other 8 samples (26.6 %) showed double heterozygous for ( β S 6 AT ) and one of β 0 -thalassemia mutations detected in our procedure as described letter , of these : 3 samples (37.5 %) showed coexistence of α -thalassemia deletion type (-3.7 kb) in one of the 4 genes (αα / α -) ( α -3.7 α / α α ) and 5 samples (62.5 %) were negative for α -thalassemia deletion (Table 3) . Three β 0 -thalassemia mutations were detected in our procedure, and their frequencies were as the follow: sex samples (75 %) were positive for IVS II-1 (G>A) mutation type, one sample (12.5 %) was positive for IVS 1-5 (G>C) mutation type and finally one sample (12.5 %) was positive for IVSII-745 (C>G) mutation type (Table 5) (Fig. 2) . 
IVSII-745 (C>G)
DISCUSSION
We studied 145 children with SCD diagnosis of SCD was based on clinical presentation suggesting sickle cell disease, clinical examination, sickling test, and hemoglobin electrophoresis as a screening methods, and HPLC method for confirmation. The sickling tests were positive in all the samples, and the hemoglobin analysis by HPLC method showed no (HbA) was detected in any of them. According to the MCV and MCH values; patients were grouped in two groups: One hundred and five patients (72.6 % ) with normal MCV and MCH were classified as HbSS, and 40 patients (27.4%) with low MCV and low MCH were classified as SCD/Thalassemia.
The diagnosis of SCD/thalassemia was based on: Presence of (80%) HbS in the HPLC with hypochromic microcytic indices (low MCV <78 fL and/or MCH < 25 pg after adjustment of the MCV for each age group) with normal or high serum ferritin. Differentiation between (α) and (β) thalassemia was not possible by the level of HbA2 , because the HbA2 value was shown to be increased in patients with HbSS due to presence of HbS adducts and may overlap in (α) and (β) thalassemia associated with HbS [6,7,8,] . For this reason we decided to do the DNA analysis for differentiation between (α) and (β) thalassemia and to explore the nature of their genetic defects and their prevalence in Yemeni SCD children. Absence of HbA from the results of HPLC indicates that the β-thalassemia mutations detected are β 0 -mutations.
For first time this study showed that in Taiz governorate the overall prevalence of HbSS with thalassemia was (27.5%) and according to DNA analysis the prevalence of HbSS+α-thalassemia and HbS/β 0 -thalassemia were (18.5% and 5.9%) respectively (After exclusion of absent 10 patients from calculation).
Βeta-Thalassemia mutations detected in Yemeni SCD children from Taiz
Over 200 different mutations of β-thalassemia have been elucidated worldwide. However, in each population a number of common mutations (usually about 5-10) exist, which account for more than (90%) of all mutations {10}. β 0 -thalassemia is endemic in the Arab countries including the countries of the Gulf region [11] . Both β 0 and β + Thalassemia have been reported and the incidence of Sickle /β-thalassemia in the Eastern region of Saudi Arabia is about (10 %) [12] .
In Yemen no previous reports have described the type of mutations that are common among the population of Yemen. In the present study we report for first time in Taiz and Yemen; β 0 -thalassemia mutations, and α-thalassemia deletion type, which confirm presence of these genetic conditions in Yemen.
In this study 30 samples were analyzed, and the results showed that 8 samples (26.6%) of them were compound heterozygous for one of the β 0 -thalassemia mutations (detected by our procedures) and codon 6 (β ). Three mutations were identified in these 8 samples studied (Table 5) . Six samples showed mutation type IVS II-1 (G > A), which was the most frequently encountered with a frequency of (75%), 1 sample showed mutation type IVSI-5 (G > C) with a frequency of (12.5 %), and 1 samples showed mutation type IVSII-745 (G > C) with a frequency of (12.5%). Most of these mutations are found in neighboring countries with varying frequencies. This is in line with studies in other parts of the world, which have shown that gene flow due to population migration is common. For example: Amein Kamel et al. [13] found that in Eastern province of Saudi Arabia four of the mutations account for 76.8% of subjects studied, and the mutations were: IVSII-1 (G > A) , IVSI-5 (G > C), codon 39, IVSI-1 (G > A) with frequencies (27.5%, 23.2%, 20.3% and 5.8%), respectively.
In the Middle East the following mutations; Codon 39 (C > T), IVSI-110 (G > A), IVSI-l (G > A), IVSI-6 (T > C), IVSII-l (G > A), codon 5 (-CT), and IVSI-5 (G > C) account for more than 90% of, β-thalassemia mutations in the region [10, 11] . These reported results showed that these mutations detected in our patients are the most frequent mutations in Arab World. For example: the IVSII-1 (G > A) mutation which is of Mediterranean origin had higher frequency of 75% in our study; in comparison with Saudi Arabia at a frequency of (27.5%) [13] , Kuwait at a frequency of (29%) [14] , and in Bahrain at a frequency of (6.1%) ( Table 5 ). The IVSI-5 (G > C) mutation which is of Asian-Indian origin had frequency of (12.5%) in our study which is low in comparison with studies from the neighboring regions ,where the frequency of IVSI-5 (G > C) mutation in the Western Province of Saudi Arabia, Bahrain, Kuwait, UAE, and Oman were (10%, 16.7%, 18.8%, 55%, and 62%) respectively [10, 11, 15, 16] . Also the mutation IVSII-745 (G > C) which is Mediterranean in origin, was found in one patient in our study at frequency of (12.3%), while it was not encountered in Saudi Arabia, Bahrain, Kuwait, UAE, and Oman [11] , but it was reported in Syria, Lebanon, Egypt, Tunis and Algeria (Table 5) .
Αlfa-Thalassemia deletions detected in Yemeni SCD children from Taiz
The combination of α-thalassemia genes with sicklecell and β-thalassemia genes occur in Middle East with varying frequencies in the different countries, and in different areas within the same country [17, 18] . Some areas particularly those with a past or present history of malaria endemicity have a high frequency of these genes For example: Saudi Arabia [3, 12, 19] .
As consanguineous marriage and marriage between members of the same tribe are common throughout the region coexisting α-thalassemia and SCD cases occur and influencing the presentation of SCD [3, 12, 20] .
This study on selected Yemeni SCD children in Taiz did not by any means give an accurate account of the (α-gene) deletion in the population of Yemen. However, the results showed that α-thalassemia had high frequency among SCD patients as follow:
Firstly, in the group overall the α-thalassemia deletion was present in 25 samples of 30 samples studied representing a high frequency of (83.3%) of those 25 samples; 17 samples were found to have one α-gene (-/αα) (α-3.7 α / α α) deletion representing (68%), and 8 were found to have 2 gene deletion (-α/-α) (α-3.7 α / α-3.7 α) representing (32%) ( Table 4) . Secondly, the frequency of α-thalassemia deletion in the total group (30 samples) was (56.6%) for one gene deletion (-α/αα) and (26.6%) for 2 gene deletions (-α/-α). Thirdly, when α-thalassemia deletions were separated according to genotypes, the frequency of one gene deletion (-α/αα) was significantly higher (63.6%) in children with HbSS than in children with (S/β 0 -thalassemia) which was (37.5%) and the frequency of 2 gene deletions (-α/-α) was (36.3%) in children with HbSS and in children with S/β 0 -thalassemia there were no cases with two gene deletions (Table 4) .
In Yemeni SCD children from Taiz and those living in Riyadh Saudi Arabia; the α-gene deletion is a rightward deletion which results in the deletion of a (3.7 kb) fragment (α -3.7 α / α α), which comprised partly of α 1 and α 2 globin genes, thus producing a hybrid gene [3] . In Yemeni patients living in Riyadh Saudi Arabia the frequency of α-thalassemia (-α/αα) and (α-thalassemia) (-α/-α) in HbSS / α-thalassemia patients were (34.6% and 23.1%), respectively [3] .
The present study showed that our results were comparable with those reported in Yemeni SCD children living in Rhyiad Saudi Arabia as deletion type and frequency [3] .
In Jordan Mohammed Wael Abu Ghoush showed that the frequency of (α -3.7 α / α α) was 43%, and the frequency of (α -3.7 α / α -3.7 α) was 30% [9] . El hazmy et al had reported a high frequency of HbS and α-thalassemia genes in the south-western region of Saudi Arabia for example: in Jizan which is situated near to the North border of Yemen the frequency of HbS, α-thalassemia silent carrier (-α/αα) ,α-thalassemia trait (-α/-α) and β-thalassemia were 0.103, 0.41, 0.12 and 0.059 respectively. In the present study cases of leftward deletion triple a-gene arrangement or nondeletion forms were not seen; although in Saudi Arabia Instances of triple a-gene arrangement leftward deletion and non-deletion forms have been identified, but at a very low frequency [3, 12, [20] [21] [22] [23] .
CONCLUSIONS
For first time in Taiz governorate and Yemen, this study showed that; the β-thalassemia mutations detected in Yemeni SCD Children were: IVS II-1 (A>T) with a frequency of (75 %), IVS I-5 (G>C) with a frequency of (12.5%), and the IVS II-745 C>G with a frequency of (12.5%). The α-thalassemia deletion type found was of right ward deletion (-3.7 kb), and 17 patients (68%) had one gene deletion, and 8 patients (32%) had two gene deletions. The α-thalassemia was more frequent among HbSS patients (63.6%) than S/β 0 -thalassemia patients (37.3%). The overall prevalence of thalassemia in SCD Yemeni children was (27.5%), and according to DNA analysis the prevalence of α-thalassemia and β 0 -thalassemia were (18.5% and 5.9%), respectively.
RECOMMENDATIONS
This study on selected SCD children from Taiz did not by any means give an accurate account of the frequencies of HbS gene, β-gene, and α-gene in population of Yemen. For this reason other population based studies are needed in all regions of Yemen to elucidate the prevalence of SCD, alpha and beta thalassemia to build a solid scientific data which help in creating a national registry of Hemoglobinopathies and thalassemia in Yemen.
